Tag: biotechnology
Acquisition of Synaffix Strengthens Lonza’s Bioconjugates Offering
In a statement earlier today, Lonza, a global manufacturing partner to the pharmaceutical, biotech and nutraceutical markets, confirmed that it has acquired Netherlands-based Synaffix, a biotechnology company focused on commercializing its clinical-stage technology platform for the development of antibody-drug conjugates (ADCs).
Eisai & Co and Bliss Biopharmaceutical (Hangzhou) Sign Agreement to Jointly...
Japanese drugmaker Eisai & Co and Chinese drug developer Bliss Biopharmaceutical (Hangzhou) Co., have entered into a joint development agreement to further develop BB-1701, an antibody-drug conjugate (ADC). As part of the agreement Eisai & Co obtained option rights for a strategic collaboration.
Amgen and Synafix Sign US $2 Billion License Agreement
Netherlands-based Synaffix, a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs), confirmed that it had signed...
SOTIO and LegoChem Biosciences Sign Exclusive Collaboration and License Agreement
Clinical stage immuno-oncology company SOTIO Biotech and LegoChem Biosciences (LCB), a biotechnology company focused on developing its clinical-stage platform technology to develop antibody-drug conjugates...
Lonza Opens News Facility for ADC Payload Manufacturing Following a Tailored...
Lonza, a specialty Contract Development and Manufacturing partner for biopharmaceutical companies, inaugurated the first of two manufacturing suites for antibody-drug conjugate (ADC) drug-linker (payload)...
Exelixis and Catalent to Jointly Develop Multiple SMARTag®-based Antibody-drug Conjugates
Alameda- (California-) based Exelixis confirmed that it has signed a partnership agreement with Catalent to develop multiple antibody-drug conjugates (ADCs) using Catalent's proprietary SMARTag®...
CPhI Worldwide Attendees Expect Global Pharma Economies to Rapidly Grow
Set against the backdrop of one of the most important business centers in Madrid, Spain, the IFEMA Feria de Madrid hosted this year's 29th...
Synaffix Secures End-to-end Patent Protection for GlycoConnect Technology
The Netherlands-based Synaffix, a biotechnology company that has developed a proprietary site-specific platform technology to enable differentiated antibody-drug conjugates (ADCs), has received a key...
Sorrento Therapeutics Completes Manufacturing Facility in China
Earlier today Sorrento Therapeutics announced that its subsidiary, Levena Biopharma, completed construction of its new, 25,000 sq/ft GMP manufacturing facility in Suzhou, China. The facility...
Synaffix’s New High Potency Lab now Fully Operational to Support Growing...
Late last week, Synaffix, a Dutch biotechnology company backed by a top tier, life science-focused, investor syndicate and the strategic corporate venture capital fund of...
